Login to Your Account



Still Hope For Hot Flashes

Depomed's PHN Pain Drug Falters In Phase III Attempt

By Randall Osborne


Wednesday, July 11, 2007
Depomed Inc. noted a strangely high and persistent placebo effect in the Phase III blowup of its postherpetic neuralgia (PHN) pain tablet Gabapentin GR, but the explanation failed to appease investors, and Wall Street shaved 59.4 percent off the value of the stock (NASDAQ:DEPO), which closed Tuesday at $2, down $2.93. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription